Fig. 2

Forest plots representing the prevalence of relapse, flare, or exacerbation in all patients with autoimmune and immune-mediated diseases (AI-IMD) before (A) and after (B) removing the outliers and based on the type of AI-IMD disease (C) following the COVID-19 vaccination. The prevalence of relapse, flare, or exacerbation was statistically significantly different across the six disease categories overall, as shown by a p-value of < 0.0001